1. Балаболкин И.И., Смирнов И.Е., Булгакова В.А. и др. Современная концепция патогенеза бронхиальной астмы у детей. Иммунопатология, аллергология, инфектология. 2006; 1: 26–35.
2. Бронхиальная астма у детей. Под ред. С.Ю.Каганова. М.: Медицина, 1999.
3. Геппе Н.А., Колосова Н.Г. К 15-летию первой Национальной программы по бронхиальной астме у детей. Пульмонология детского возраста: проблемы и решения. Вып. 13. Под ред. Ю.Л.Мизерницкого, А.Д.Царегородцева. 2013; с. 204–12.
4. Геппе Н.А., Фарбер И.М. Применение антагониста лейко­триеновых рецепторов монтелукаста для лечения бронхиальной астмы у детей первых лет жизни. Пульмонология. 2009; 5: 113–8.
5. Каганов С.Ю., Круглый Б.И., Сулаквилидзе И.В. Аспириновая астма у детей. Педиатрия. 1988; 10: 56–60.
6. Княжеская Н.П. Антагонисты лейкотриеновых рецепто­ров-противовоспалительные препараты для лечения бронхиальной астмы. Cons. Med. 2013; 11: 13–6.
7. Мизерницкий Ю.Л. Бронхиальная астма. В кн.: Хронические заболевания легких у детей. Под ред. Н.Н.Розиновой, Ю.Л.Мизерницкого. М.: Практика, 2011; с. 149–68.
8. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 4-е изд. М., 2012.
9. Тулуевская Л. Роль медиаторов липидной природы в патогенезе немедленной аллергии. Автореф. дис. ... канд. биол. наук. М., 1992.
10. Baek HS, Cho J, Kim JH et al. Ratio of leukotriene e(4) to exhaled nitric oxide and the therapeutic response in children with exercise-induced bronchoconstriction. Allergy Asthma Immunol Res. 2013; 
5 (1): 26–33.
11. Barnes N. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med 2000; 161: S73–S76.
12. Berube D, Djandji M, Sampalis JS, Becker A. Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study. Allergy Asthma Clin Immunol 2014, 10 (1): 21.
13. Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171 (4): 315–22.
14. Byrne PM. Leukotriene bronchoconstriction induced by allergen and exercise. Am J Respir Crit Care Med 2000; 161 (Suppl.): S68–72.
15. Callero-Viera A, Infante S, Fuentes-Aparicio V et al. Neuropsychiatric reactions to montelukast. 
J Investig Allergol Clin Immunol 2012; 22 (6): 452–3.
16. Csoma Z, Kharitonov SA, Balint B et al. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2002; 166: 1345–9.
17. Dockhorn RJ, Baumgartner RA, Leff JA et al. Comparison of the effects of intravenous and oral montelucast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax 2000; 55: 260–5.
18. Fedberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938; 94 (2); 187–226.
19. Henderson WR Jr, Chiang GKS, Tien Y-T et al. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173: 718–28.
20. Holgate S, Sampson A. Antileukotriene therapy. Am J Respir Crit Care Med 2000; 161: S147–S153.
21. Knorr B, Franchi LM, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persient asthma in children aged 2 to 5 years. Pediatrics 2001; 108 (3): E48.
22. Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in to children: a randomized trial. Pediatric Montelukast Study Group.  JAMA 1998; 279 (15): 1181–6.
23. Kocyigit A, Gulcan Oksuz B, Yarar F et al. Hallucination development with montelukast in a child with asthma: case presentation. Iran J Allergy Asthma Immunol 2013; 12 (4): 397–9.
24. Malonne H, Lachman A, van den Brande P. Impact of montelukast on symptoms in mild-to-moderate persistent asthma and exercise-induced asthma: results of the ASTHMA survey. Curr Med Res Opin 2002; 18 (8): 512–9.
25. Massingham K, Fox S, Smaldone A. Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. J Pediatr Health Care 2014; 28 (1): 51–62.
26. Pauwels RA, Joos GF, Kips JC. Leukotrienes as therapeutic target in asthma. Allergy 1995; 50: 615–22.
27. Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J  1999; 14: 12–8.
28. Scadding GW, Scadding GK. Recent advances in antileukotriene therapy. Curr Opin Allergy Clin Immunol 2010; 10 (4): 370–6.
29. Stanford RH, Shah M, Chaudhari SL. Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast inchildren with asthma aged 4 to 11 years. Open Respir Med J 2012; 6: 37–43.
30. Szczeklik A, Stevenson D. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104: 5–3.
31. Visitsunthorn N, Chirdjirapong V, Santadilog S et al. The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6–13 years. Asian Pac J Allergy Immunol 2011; 29 (2): 127–33.
32. Virchowa JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006; 100: 1952–9.
33. Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther 2008; 30: 1026–35.
34. Зайцева О.В. Бронхиальная астма и респираторные инфекции у детей. Медицинский совет. 2013; 1: 34–41.

Ю.Л.Мизерницкий

НИКИ педиатрии ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва